Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Gregory A Yanik

Showing results (41-50 of 78) with videos related to

Pageof 8
Sort By:
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|July 28, 2015
Reducing Treatment-Related Mortality Did Not Improve Outcomes of Allogeneic Myeloablative Hematopoietic Cell Transplantation for High-Risk Multiple Myeloma: A University of Michigan Prospective SeriesAttaphol Pawarode, Shin Mineishi, Pavan Reddy, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|October 2, 2014
TNF-receptor inhibitor therapy for the treatment of children with idiopathic pneumonia syndrome. A joint Pediatric Blood and Marrow Transplant Consortium and Children's Oncology Group Study (ASCT0521)Gregory A Yanik, Stephan A Grupp, Michael A Pulsipher, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|June 16, 2012
Dose escalation study of no-carrier-added 131I-metaiodobenzylguanidine for relapsed or refractory neuroblastoma: new approaches to neuroblastoma therapy consortium trialKatherine K Matthay, Brian Weiss, Judith G Villablanca, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|March 11, 2014
Randomized, double-blind, placebo-controlled trial of soluble tumor necrosis factor receptor: enbrel (etanercept) for the treatment of idiopathic pneumonia syndrome after allogeneic stem cell transplantation: blood and marrow transplant clinical trials network protocolGregory A Yanik, Mary M Horowitz, Daniel J Weisdorf, et al.
Blood|November 18, 2020
A validated pediatric disease risk index for allogeneic hematopoietic cell transplantationMuna Qayed, Kwang Woo Ahn, Carrie L Kitko, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 13, 2011
Phase II study of oral capsular 4-hydroxyphenylretinamide (4-HPR/fenretinide) in pediatric patients with refractory or recurrent neuroblastoma: a report from the Children's Oncology GroupJudith G Villablanca, Wendy B London, Arlene Naranjo, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|September 10, 2017
Validation of Postinduction Curie Scores in High-Risk Neuroblastoma: A Children's Oncology Group and SIOPEN Group Report on SIOPEN/HR-NBL1Gregory A Yanik, Marguerite T Parisi, Arlene Naranjo, et al.
Blood Advances|June 24, 2025
Evaluation of in vivo CAR transgene levels in tisagenlecleucel-treated patients with relapsed/refractory B-ALL and DLBCLRakesh Awasthi, Stephan A Grupp, Edward R Waldron, et al.
Blood|February 14, 2018
α<sub>1</sub>-Antitrypsin infusion for treatment of steroid-resistant acute graft-versus-host diseaseJohn M Magenau, Steven C Goldstein, Dan Peltier, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|February 3, 2015
131I-metaiodobenzylguanidine with intensive chemotherapy and autologous stem cell transplantation for high-risk neuroblastoma. A new approaches to neuroblastoma therapy (NANT) phase II studyGregory A Yanik, Judith G Villablanca, John M Maris, et al.
Pageof 8

Showing results (41-50 of 78) with videos related to

Sort By:
Pageof 8
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|July 28, 2015
Reducing Treatment-Related Mortality Did Not Improve Outcomes of Allogeneic Myeloablative Hematopoietic Cell Transplantation for High-Risk Multiple Myeloma: A University of Michigan Prospective SeriesAttaphol Pawarode, Shin Mineishi, Pavan Reddy, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|October 2, 2014
TNF-receptor inhibitor therapy for the treatment of children with idiopathic pneumonia syndrome. A joint Pediatric Blood and Marrow Transplant Consortium and Children's Oncology Group Study (ASCT0521)Gregory A Yanik, Stephan A Grupp, Michael A Pulsipher, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|June 16, 2012
Dose escalation study of no-carrier-added 131I-metaiodobenzylguanidine for relapsed or refractory neuroblastoma: new approaches to neuroblastoma therapy consortium trialKatherine K Matthay, Brian Weiss, Judith G Villablanca, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|March 11, 2014
Randomized, double-blind, placebo-controlled trial of soluble tumor necrosis factor receptor: enbrel (etanercept) for the treatment of idiopathic pneumonia syndrome after allogeneic stem cell transplantation: blood and marrow transplant clinical trials network protocolGregory A Yanik, Mary M Horowitz, Daniel J Weisdorf, et al.
Blood|November 18, 2020
A validated pediatric disease risk index for allogeneic hematopoietic cell transplantationMuna Qayed, Kwang Woo Ahn, Carrie L Kitko, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 13, 2011
Phase II study of oral capsular 4-hydroxyphenylretinamide (4-HPR/fenretinide) in pediatric patients with refractory or recurrent neuroblastoma: a report from the Children's Oncology GroupJudith G Villablanca, Wendy B London, Arlene Naranjo, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|September 10, 2017
Validation of Postinduction Curie Scores in High-Risk Neuroblastoma: A Children's Oncology Group and SIOPEN Group Report on SIOPEN/HR-NBL1Gregory A Yanik, Marguerite T Parisi, Arlene Naranjo, et al.
Blood Advances|June 24, 2025
Evaluation of in vivo CAR transgene levels in tisagenlecleucel-treated patients with relapsed/refractory B-ALL and DLBCLRakesh Awasthi, Stephan A Grupp, Edward R Waldron, et al.
Blood|February 14, 2018
α<sub>1</sub>-Antitrypsin infusion for treatment of steroid-resistant acute graft-versus-host diseaseJohn M Magenau, Steven C Goldstein, Dan Peltier, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|February 3, 2015
131I-metaiodobenzylguanidine with intensive chemotherapy and autologous stem cell transplantation for high-risk neuroblastoma. A new approaches to neuroblastoma therapy (NANT) phase II studyGregory A Yanik, Judith G Villablanca, John M Maris, et al.
Pageof 8